These results demonstrate that CARD11 is a bona fide oncogene in DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
这些结果表明在DLBCL中，CARD11是真正的癌基因，对DLBCL治疗中用药物抑制CARD11通路提供了遗传学理论。
It is the first to demonstrate that combining human monoclonal antibodies with cytokines can be an effective cancer therapy.
它是首次阐明了细胞因子联合人单克隆抗体可以有效地治疗癌症。
应用推荐